nach oben

Der Nervenarzt

Erschienen in:

01.06.2008 | Amyotrophe Lateralsklerose | Übersichten

Amyotrophe Lateralsklerose

Aktuelle klinische Studien und ihr pathogenetischer Hintergrund

verfasst von: Dr. K. Kollewe, R. Dengler, S. Petri

Erschienen in: Der Nervenarzt | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die amyotrophe Lateralsklerose (ALS) ist eine neurodegenerative Erkrankung, die innerhalb von 3–5 Jahren zum Tode führt. Die bisher einzige Substanz mit marginalem therapeutischem Potenzial ist der Glutamatantagonist Riluzol, der jedoch nur zu einer durchschnittlichen Lebensverlängerung von 3–4 Monaten führt. Daher hat die symptomatische Therapie einen hohen Stellenwert. In zahlreichen tierexperimentellen und klinischen Studien werden potenziell neuroprotektive Wirkstoffe für eine kausale Behandlung untersucht. In diesem Übersichtsartikel sollen im Kontext mit den zugrunde liegenden Wirkmechanismen aktuelle klinischen ALS-Studien vorgestellt werden.

Almer G, Guegan C, Teismann P et al. (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49: 176–185PubMedCrossRef

Almer G, Teismann P, Stevic Z et al. (2002) Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58: 1277–1279PubMed

Angelov DN, Waibel S, Guntinas-Lichius O et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100: 4790–4795PubMedCrossRef

Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357–366PubMedCrossRef

Beal MF, Ferrante RJ, Browne SE et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644–654PubMedCrossRef

Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585–591PubMedCrossRef

Borasio GD, Robberecht W, Leigh PN et al. (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51: 583–586PubMed

Bowling AC, Schulz JB, Brown RH Jr, Beal MF (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61: 2322–2325PubMedCrossRef

Brooks B, Sanjak M, Roelke K et al. (2005) Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in ALS: sensitivity analyses of discordance between survival and fucitonal outcomes with long-term follow-up. Amyotroph Lateral Scler Other Motor Neuron Disord [Suppl 1] 6: 118

10.

Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723–749PubMedCrossRef

11.

Carri MT, Grignaschi G, Bendotti C (2006) Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27: 267–273PubMedCrossRef

12.

Chou SM, Wang HS, Taniguchi A, Bucala R (1998) Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Medicine 4: 324–332

13.

Clement AM, Nguyen MD, Roberts EA et al. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113–117PubMedCrossRef

14.

Crow JP, Calingasan NY, Chen J et al. (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258–265PubMedCrossRef

15.

Cudkowicz M, Shefner, J, Simpson E et al. (2006) A multicenter, dose ranging safety and pharmacokinetics study of arimoclomol in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 7: 113

16.

Danzeisen R, Schwalenstoecker B, Gillardon F et al. (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316: 189–199PubMedCrossRef

17.

Di Giorgio FP, Carrasco MA, Siao MC et al. (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608–614CrossRef

18.

Do TQ, Schultz JR, Clarke CF (1996) Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proc Natl Acad Sci U S A 93: 7534–7539PubMedCrossRef

19.

Dobrowolny G, Giacinti C, Pelosi L et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168: 193–199PubMedCrossRef

20.

Drachman DB, Frank K, Dykes-Hoberg M et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771–778PubMedCrossRef

21.

Ferrante KL, Shefner J, Zhang H et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834–1836PubMedCrossRef

22.

Ferrante RJ, Browne SE, Shinobu LA et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064–2074PubMedCrossRef

23.

Ferrante RJ, Shinobu LA, Schulz JB et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326–334PubMedCrossRef

24.

Gordon PH, Moore DH, Gelinas DF et al. (2004) Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62: 1845–1847PubMed

25.

Greig NH, Mattson MP, Perry T et al. (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1035: 290–315PubMedCrossRef

26.

Guegan C, Vila M, Rosoklija G et al. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 21: 6569–6576PubMed

27.

Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA (2000) Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 30: 205–207PubMedCrossRef

28.

Gurney ME, Cutting FB, Zhai P et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157PubMedCrossRef

29.

Hargitai J, Lewis H, Boros I et al. (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307: 689–695PubMedCrossRef

30.

Haverkamp LJ, Smith RG, Appel SH (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 36: 253–254PubMedCrossRef

31.

Henkel JS, Engelhardt JI, Siklos L et al. (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221–235PubMedCrossRef

32.

Hensley K, Fedynyshyn J, Ferrell S et al. (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74–80PubMedCrossRef

33.

Hensley K, Floyd RA, Gordon B et al. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82: 365–374PubMedCrossRef

34.

Hu JH, Zhang H, Wagey R et al. (2003) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 85: 432–442PubMedCrossRef

35.

Kaspar BK, Llado J, Sherkat N et al. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839–842PubMedCrossRef

36.

Katsumata S, Tateishi N, Kagamiishi Y et al. (1999) Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultered astrocytes and ischemic brain. Soc Neurosci 11: 843 (Abstr)

37.

Kiaei M, Kipiani K, Petri S et al. (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegen Dis 2: 246–254CrossRef

38.

Kiaei M, Petri S, Kipiani K et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26: 2467–2473PubMedCrossRef

39.

Kieran D, Kalmar B, Dick JR et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402–405PubMedCrossRef

40.

Klivenyi P, Kiaei M, Gardian G et al. (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88: 576–582PubMedCrossRef

41.

Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139PubMedCrossRef

42.

Kriz J, Nguyen MD, Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268–278PubMedCrossRef

43.

Lacomblez L, Bensimon G, Leigh PN et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425–1431PubMed

44.

Lai EC, Felice KJ, Festoff BW et al. (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49: 1621–1630PubMed

45.

Lambrechts D, Lafuste P, Carmeliet P, Conway EM (2006) Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends Mol Med 12: 345–347PubMedCrossRef

46.

Mackenzie IR, Bigio EH, Ince PG et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61: 427–434PubMedCrossRef

47.

Matthews RT, Yang L, Browne S et al. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892–8897PubMedCrossRef

48.

Mercuri E, Bertini E, Messina S et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14: 130–135PubMedCrossRef

49.

Meyer T MA, Borisow N, Dullinger J et al. (2007) Thalidomide causes sinus bradycardia in ALS. Akt Neurol 34: 69

50.

Nagai M, Re DB, Nagata T et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615–622PubMedCrossRef

51.

Neumann M, Sampathu DM, Kwong LK et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133PubMedCrossRef

52.

Nilsson M, Hansson E, Ronnback L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17: 327–332PubMedCrossRef

53.

Oteiza PI, Uchitel OD, Carrasquedo F et al. (1997) Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 22: 535–539PubMedCrossRef

54.

Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW (2000) Caspase-1 and −3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 97: 13901–13906PubMedCrossRef

55.

Patel M, Day BJ (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 20: 359–364PubMedCrossRef

56.

Petri S, Kiaei M, Kipiani K et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40–49PubMedCrossRef

57.

Rosen DR, Siddique T, Patterson D et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62PubMedCrossRef

58.

Rothstein JD, Van Kammen M, Levey AI et al. (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84PubMedCrossRef

59.

Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344: 1688–1700PubMedCrossRef

60.

Ryu H, Smith K, Camelo SI et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087–1098PubMedCrossRef

61.

Sekizawa T, Openshaw H, Ohbo K et al. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154: 194–199PubMedCrossRef

62.

Shefner JM, Cudkowicz ME, Schoenfeld D et al. (2004) A clinical trial of creatine in ALS. Neurology 63: 1656–1661PubMed

63.

Shibata N, Nagai R, Uchida K et al. (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97–104PubMedCrossRef

64.

Siklos L, Engelhardt J, Harati Y et al. (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 39: 203–216PubMedCrossRef

65.

Smith RG, Henry YK, Mattson MP, Appel SH (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696–699PubMedCrossRef

66.

Storkebaum E, Lambrechts D, Dewerchin M et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85–92PubMedCrossRef

67.

Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136–143PubMedCrossRef

68.

Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64: 649–664PubMedCrossRef

69.

Sugai F, Yamamoto Y, Miyaguchi K et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179–3183PubMedCrossRef

70.

Tan CF, Eguchi H, Tagawa A et al. (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (Berl) 113: 535–542

71.

Traynor BJ, Bruijn L, Conwit R et al. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67: 20–27PubMedCrossRef

72.

Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067–1070CrossRef

73.

Van Muiswinkel FL, Kuiperij HB (2005) The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets 4: 267–281CrossRef

74.

Wang R, Zhang D (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22: 2376–2380PubMedCrossRef

75.

Wilms H, Sievers J, Dengler R et al. (2003) Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 144: 139–142PubMedCrossRef

76.

Wu AS, Kiaei M, Aguirre N et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142–150PubMedCrossRef

77.

Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35: 419–432PubMedCrossRef

78.

Yim MB, Kang JH, Yim HS et al. (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci U S A 93: 5709–5714PubMedCrossRef

79.

Yoshihara T, Ishigaki S, Yamamoto M et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80: 158–167PubMedCrossRef

80.

Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267–270PubMedCrossRef

81.

Zhu S, Stavrovskaya IG, Drozda M et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74–78PubMedCrossRef

Titel: Amyotrophe Lateralsklerose
Aktuelle klinische Studien und ihr pathogenetischer Hintergrund
verfasst von: Dr. K. Kollewe
R. Dengler
S. Petri
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Schlagwörter: Amyotrophe Lateralsklerose
Seltene Erkrankungen
Erschienen in: Der Nervenarzt / Ausgabe 6/2008
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-007-2403-0

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

Amyotrophe Lateralsklerose

Aktuelle klinische Studien und ihr pathogenetischer Hintergrund

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

ERlanger Neurologisches Examen – STrukturiert (ERNEST)

Neurotuberkulose

Neurolymphomatose

Mitteilungen der DGPPN 6/08

Elektive Termination der Beatmungstherapie bei der amyotrophen Lateralsklerose

Zwischen Patientenautonomie und ärztlicher Garantenstellung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus